Postmenopausal tamoxifen treatment and endometrial pathology.
Tamoxifen is widely used as adjuvant therapy for postmenopausal breast cancer patients with positive estrogen receptors. Data on a possible association of endometrial pathologies with tamoxifen treatment have been accumulating. In this review, we examine the current literature and include our own experience with this occurrence. We recommend close supervision of these patients.
Cohen
I
I
Department of Obstetrics and Gynecology, Sapir Medical Center, Kfar Saba, Israel.
Altaras
M M
MM
Shapira
J
J
Tepper
R
R
Beyth
Y
Y
D001940:Breast / Q000187:drug effects* / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004714:Endometrial Hyperplasia / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D004715:Endometriosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017698:Postmenopause; D013629:Tamoxifen / Q000009:adverse effects* / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D014463:Ultrasonography
D013629:Tamoxifen